FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144691807> ?p ?o ?g. }

• W2144691807 endingPage "1364" @default.
• W2144691807 startingPage "1354" @default.
• W2144691807 abstract "Background. Celecoxib and meloxicam are classified as cyclooxygenase (COX)-2 selective inhibitors. The Drug Safety Research Unit monitored the post marketing safety of these drugs in England using the non-interventional observational cohort technique of Prescription-Event Monitoring (PEM). Objectives. To compare the incidence rates of selected thromboembolic (TE) (cardiovascular, cerebrovascular and peripheral venous thrombotic) events reported for patients prescribed celecoxib and meloxicam in general practice. Methods. Patients were identified from dispensed prescriptions written by general practitioners (GPs) for meloxicam (December 1996–March 1997) and celecoxib (May and December 2000). Simple questionnaires requesting details of events occurring during/after treatment, indication and potential risk factors (including age, sex and whether NSAIDs had been prescribed within 3 months of treatment) were posted to prescribing GPs at least 6 months after the first prescription for each patient. Incidence rates of the first event were calculated; crude and adjusted rate ratios (RRs) were obtained using Poisson regression modelling. Results. During the 9 months after starting treatment, 28 (0.16%) and 19 (0.10%) of patients were reported to have experienced cardiovascular TE events, 68 (0.39%) and 52 (0.27%) cerebrovascular TE events, and 17 (0.10%) and 20 (0.10%) experienced peripheral venous thrombotic events for celecoxib and meloxicam, respectively. Regarding time to first event, there was a persistent divergence between the two drugs from 30 days after the start of treatment for both the cardiovascular TE event group (log rank test P = 0.0153) and cerebrovascular TE event group (log rank test P = 0.0055). Indication and use of an NSAID within 3 months prior to starting treatment had no effect on the relative risk estimates of the event groups and was excluded in subsequent analyses. Adjusting for the two identified risk factors of age (age2) and sex, the cerebrovascular TE event group rate was higher for celecoxib than for meloxicam, RR 1.66 (95% CI 1.10–2.51), over the study period and no different for the cardiovascular TE event group, RR 1.72 (95% CI 0.87–3.40) or peripheral venous thrombotic group, RR 1.06 (95% CI 0.51–2.19). Conclusions. This study reports a relative increase in the rate of cerebrovascular TE events in users of celecoxib compared to meloxicam. There was no difference in the rate of cardiovascular TE events or peripheral venous thrombotic events between users of these two drugs. The incidence of these three groups of events reported in each of these two drug cohorts was low (<0.5%), therefore the relevance of our findings need to be taken into consideration with other clinical and pharmacoepidemiological studies." @default.
• W2144691807 created "2016-06-24" @default.
• W2144691807 creator A5082637236 @default.
• W2144691807 date "2003-07-16" @default.
• W2144691807 modified "2023-10-16" @default.
• W2144691807 title "Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data" @default.
• W2144691807 cites W107715711 @default.
• W2144691807 cites W1506237988 @default.
• W2144691807 cites W1509047972 @default.
• W2144691807 cites W1517947046 @default.
• W2144691807 cites W1521527718 @default.
• W2144691807 cites W1524299374 @default.
• W2144691807 cites W1565253767 @default.
• W2144691807 cites W1844014513 @default.
• W2144691807 cites W1903126779 @default.
• W2144691807 cites W1945208946 @default.
• W2144691807 cites W1972632012 @default.
• W2144691807 cites W1972821304 @default.
• W2144691807 cites W1974179017 @default.
• W2144691807 cites W1977473142 @default.
• W2144691807 cites W1980242785 @default.
• W2144691807 cites W1985543382 @default.
• W2144691807 cites W2013166307 @default.
• W2144691807 cites W2020563114 @default.
• W2144691807 cites W2022050717 @default.
• W2144691807 cites W2028950040 @default.
• W2144691807 cites W2030695435 @default.
• W2144691807 cites W2031340028 @default.
• W2144691807 cites W2034468337 @default.
• W2144691807 cites W2038410983 @default.
• W2144691807 cites W2040222397 @default.
• W2144691807 cites W2059674080 @default.
• W2144691807 cites W2063841251 @default.
• W2144691807 cites W2073283371 @default.
• W2144691807 cites W2081898970 @default.
• W2144691807 cites W2095797387 @default.
• W2144691807 cites W2100822604 @default.
• W2144691807 cites W2115054720 @default.
• W2144691807 cites W2115679325 @default.
• W2144691807 cites W2118794261 @default.
• W2144691807 cites W2119140309 @default.
• W2144691807 cites W2121852158 @default.
• W2144691807 cites W2122120608 @default.
• W2144691807 cites W2123036067 @default.
• W2144691807 cites W2130422962 @default.
• W2144691807 cites W2145271885 @default.
• W2144691807 cites W2145816148 @default.
• W2144691807 cites W2147257042 @default.
• W2144691807 cites W2156835501 @default.
• W2144691807 cites W2160685542 @default.
• W2144691807 cites W2162398860 @default.
• W2144691807 cites W2163756514 @default.
• W2144691807 cites W2164397284 @default.
• W2144691807 cites W2172253009 @default.
• W2144691807 cites W2187397917 @default.
• W2144691807 cites W2256824405 @default.
• W2144691807 cites W2330496155 @default.
• W2144691807 cites W2464901533 @default.
• W2144691807 cites W2471116638 @default.
• W2144691807 cites W2750016830 @default.
• W2144691807 cites W3204350 @default.
• W2144691807 cites W50807861 @default.
• W2144691807 cites W627791993 @default.
• W2144691807 cites W6953988 @default.
• W2144691807 cites W97893626 @default.
• W2144691807 cites W2186012206 @default.
• W2144691807 doi "https://doi.org/10.1093/rheumatology/keg401" @default.
• W2144691807 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12867585" @default.
• W2144691807 hasPublicationYear "2003" @default.
• W2144691807 type Work @default.
• W2144691807 sameAs 2144691807 @default.
• W2144691807 citedByCount "51" @default.
• W2144691807 countsByYear W21446918072012 @default.
• W2144691807 countsByYear W21446918072013 @default.
• W2144691807 countsByYear W21446918072014 @default.
• W2144691807 countsByYear W21446918072015 @default.
• W2144691807 countsByYear W21446918072016 @default.
• W2144691807 countsByYear W21446918072022 @default.
• W2144691807 crossrefType "journal-article" @default.
• W2144691807 hasAuthorship W2144691807A5082637236 @default.
• W2144691807 hasBestOaLocation W21446918071 @default.
• W2144691807 hasConcept C120665830 @default.
• W2144691807 hasConcept C121332964 @default.
• W2144691807 hasConcept C126322002 @default.
• W2144691807 hasConcept C194828623 @default.
• W2144691807 hasConcept C197636746 @default.
• W2144691807 hasConcept C197934379 @default.
• W2144691807 hasConcept C23131810 @default.
• W2144691807 hasConcept C2426938 @default.
• W2144691807 hasConcept C2776467144 @default.
• W2144691807 hasConcept C2779751750 @default.
• W2144691807 hasConcept C2908647359 @default.
• W2144691807 hasConcept C50382708 @default.
• W2144691807 hasConcept C61511704 @default.
• W2144691807 hasConcept C71924100 @default.
• W2144691807 hasConcept C72563966 @default.
• W2144691807 hasConcept C73269764 @default.
• W2144691807 hasConcept C98274493 @default.

• next